Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07048665

Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver

"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AYK Hospital

Lahore, Pakistan

About this study

This will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both Male and Female.
  • Patients diagnosed with HCC who underwent TACE.
  • Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
  • Patients who underwent TACE within last your years from the study start date.

Exclusion criteria

  • Patients with incomplete or missing medical records and imaging studies.
  • Patients with a history of severe comorbidities that might interfere with treatment response evaluation
  • Patients who were contraindicated for CT scans at the time of follow-up.
  • Patients that are contradicted with CT scan.
  • Patient who underwent TACE more than four years before the study period.

Treatment and study plan

CT Imagesa in HCCT

Diagnostic Test

Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter

Primary outcomes

  1. self admisistered questioner

    Time frame: 12 Months

    self-administered questionnaire for the evaluation of HCCT, having a score range from 0 to 50.

    The more the score shows that issues worsen.

Sponsors and collaborators

Lead sponsor

Superior University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jul 2, 2025
Registry last updated
Jul 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.